Dr Zulf Masters, OBE
CEO and Founder, Masters Speciality Pharma
Despite ongoing advancements in medicine, many rare diseases remain under-researched and underserved, particularly in emerging markets where access to effective treatment options is not only challenging but often impossible.
A global pharmaceutical company is partnering with innovative life-science companies to commercialise rare disease medicines in these challenging regions.
Improving access to essential medicine
Masters Speciality Pharma partners with innovative life-science companies to commercialise life-saving medicines. Their mission is grounded in addressing the unmet needs of patients, by improving access to essential treatments.
Dr Zulf Masters, OBE, CEO and Founder, shares the origin of the company. “I spent many years working with healthcare professionals around Latin America. It became clear to me; patients had very little access to affordable treatments,” he says.
“There are over 7,000 rare diseases, but only around 750 available treatments despite ongoing research in rare diseases. We bridge the gap by ensuring these treatments reach those who need them, regardless of geographical or economic barriers.”
Empathy, perseverance and understanding the patient’s journey are key.
Overcoming rare disease challenges
Facilitating access to medicines in emerging markets comes with a host of unique challenges; healthcare budgets for rare diseases are spent with caution, and these budgets can be very limited. The regulatory environment is constantly changing, and every country has its bureaucratic nuances.
“I always maintain that, at the end of every delivery we make, there is a patient, either in hospital or at home, in pain, who needs to be treated. We need to be inclusive if we are to bridge the gap between medical advancements and the often-overlooked needs of those with rare diseases,” Masters continues.
“We have over 40 years of experience overcoming these challenges. Our team has the expertise needed to navigate these regulatory landscapes, negotiate health technology assessments and establish a reliable supply chain, ensuring continuous access to essential medicines in our end-to-end service.”
Collaboration is key to success
The company’s success is rooted in its collaborative approach. Partnering with Masters Speciality Pharma gives you in-house regulatory, medical and pharmacovigilance, as well as sales, marketing and supply-chain expertise.
“Not just the patients, but their caregivers, doctors, nurses and relatives all have an appreciation for the value we provide in ensuring these patients have access to appropriate treatments,” explains Masters.
“Empathy, perseverance and understanding the patient’s journey are key. We are making strides in several disease areas including sickle cell disease and paroxysmal nocturnal haemoglobinuria (PNH). Our partners rely on our expertise to reach patients in the most challenging markets.”
For more information, visit www.mastersglobal.com
